- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Transcenta Therapeutics Appoints New Head of Global Partnerships
Dr. Christopher Hwang will lead execution of the company's HiCB platform licensing strategy.
Mar. 30, 2026 at 2:13pm
Got story updates? Submit your updates here. ›
Transcenta Therapeutics, a global clinical-stage biopharmaceutical company, has appointed Dr. Christopher Hwang as the new Head of Global Partnerships for its Highly Intensified Continuous Bioprocessing (HiCB) platform. In this role, Hwang will lead Transcenta's efforts to license the HiCB technology to global partners, driving implementation and value creation from the platform.
Why it matters
Transcenta's HiCB platform offers a more efficient and cost-effective solution for biologics manufacturing compared to traditional fed-batch processes. By licensing this technology, Transcenta aims to help partners enhance productivity, lower costs, and increase manufacturing flexibility, ultimately improving access to important therapies worldwide.
The details
Dr. Hwang, who holds a PhD in Biochemical Engineering from MIT, brings over 30 years of experience in biopharmaceutical CMC, technology development, and manufacturing. He previously served as Transcenta's Chief Technology Officer and Executive Vice President of Process Development, playing a key role in building the HiCB platform. In his new role, Hwang will lead global partnerships to drive implementation and value creation from the HiCB technology.
- In late 2025, Dr. Hwang led Transcenta's efforts to execute a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc.
The players
Transcenta Therapeutics
A global clinical-stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing.
Dr. Christopher Hwang
The new Head of Global Partnerships for Transcenta's Highly Intensified Continuous Bioprocessing (HiCB) platform, with over 30 years of experience in biopharmaceutical CMC, technology development, and manufacturing.
EirGenix Inc.
A Taiwanese biopharmaceutical company that was granted a non-exclusive license to Transcenta's HiCB platform in late 2025.
What they’re saying
“Transcenta's HiCB platform offers a pragmatic and scalable solution to the rising costs and complexity in biologics manufacturing. I look forward to working closely with global partners, sharing our expertise, and exploring innovative ways to improve the efficiency, quality, and accessibility of therapies worldwide.”
— Dr. Christopher Hwang, Head of Global Partnerships, Transcenta Therapeutics
What’s next
Transcenta is expanding its global partner network through additional non-exclusive licensing agreements for the HiCB platform, helping partners enhance efficiency, lower costs, and increase manufacturing flexibility.
The takeaway
Transcenta's innovative HiCB platform has the potential to revolutionize biologics manufacturing by significantly improving productivity and reducing costs, ultimately making important therapies more accessible to patients worldwide. The company's strategy of licensing this technology to global partners aligns with its mission to advance the development and availability of next-generation biotherapeutics.
